Asia Pacific Genome Editing Market Size & Outlook
Asia Pacific genome editing market, 2018-2030 (US$M)
Related Markets
Asia Pacific genome editing market highlights
- The Asia Pacific genome editing market generated a revenue of USD 1,070.3 million in 2023.
- The market is expected to grow at a CAGR of 19.6% from 2024 to 2030.
- In terms of segment, (crispr)/cas9 was the largest revenue generating technology in 2023.
- (CRISPR)/Cas9 is the most lucrative technology segment registering the fastest growth during the forecast period.
- Country-wise, India is expected to register the highest CAGR from 2024 to 2030.
Asia Pacific data book summary
| Market revenue in 2023 | USD 1,070.3 million |
| Market revenue in 2030 | USD 3,743.8 million |
| Growth rate | 19.6% (CAGR from 2023 to 2030) |
| Largest segment | (crispr)/cas9 |
| Fastest growing segment | (CRISPR)/Cas9 |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | (CRISPR)/Cas9, TALENs/MegaTALs, ZFN, Meganuclease |
| Key market players worldwide | Merck KGaA, Cibus Inc Ordinary Shares - Class A, Recombinetics, Sangamo Therapeutics Inc, Editas Medicine Inc, Precision BioSciences Inc, CRISPR Therapeutics AG, Intellia Therapeutics Inc, Caribou Biosciences Inc Ordinary Shares, Cellectis SA, AstraZeneca PLC, Takara Bio Inc, Horizon Discovery, Danaher Corp, Genscript Biotech Corp Class H, New England Biolabs, Origene Technologies, Bluebird bio Inc, Lonza Group Ltd, Thermo Fisher Scientific Inc |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 13.4% of the global genome editing market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 3,743.8 million by 2030.
(crispr)/cas9 was the largest segment with a revenue share of 45.6% in 2024. Horizon Databook has segmented the Asia Pacific genome editing market based on (crispr)/cas9, talens/megatals, zfn, meganuclease covering the revenue growth of each sub-segment from 2018 to 2030.
An increasing number of Japanese companies are acquiring licenses to the CRISPR-Cas9 technology, potentially driving market growth. For instance, in July 2021, ERS Genomics declared a license agreement with Nippon Gene to grant Nippon gene access to ERS Genomics’ CRISPR/Cas9 genome editing portfolio.
Efforts undertaken by government agencies to boost development of genetically modified food products are anticipated to accelerate utilization of genome editing technology in product development methods. For instance, in December 2019, the Consumer Affairs Agency (CAA) declared that foods made using genome editing techniques are not required to undergo safety inspections.
Moreover, according to CAA, companies are also not required to submit reports on the products developed using this technology to the government. In addition, increasing prevalence of genetic diseases and diabetics coupled with growing genomic research initiatives is expected to drive the market in Japan.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Genome Editing Market Scope
Genome Editing Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Asia Pacific genome editing market size, by country, 2018-2030 (US$M)
Asia Pacific Genome Editing Market Outlook Share, 2024 & 2030 (US$M)
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
